Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737332 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT02737332 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 53 participants.
The verdict
NCT02737332, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
Interventions
- DRUG Zytiga® (Abiraterone Acetate)
- DRUG SoluMatrix™ (Abiraterone Acetate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-03-21 |
| Est. Completion | 2017-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02737332
The ClinicalTrials.gov registry entry for NCT02737332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zytiga® (Abiraterone Acetate) is the first listed.
NCT02737332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02737332 about?
NCT02737332 is a clinical study titled "A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
What is the current status of trial NCT02737332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2016-03-21. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02737332?
The interventions under investigation include: Zytiga® (Abiraterone Acetate) (DRUG), SoluMatrix™ (Abiraterone Acetate) (DRUG).
Who is sponsoring clinical trial NCT02737332?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.